India Medical Devices Market: size, import dependence, PLI and outlook 2026–2032

India’s medical devices market is growing faster than almost any large market, driven by hospital-bed expansion, insurance, diagnostics growth and government manufacturing incentives. Published estimates for 2025 range from USD 15.2 bn to USD 22.5 bn; our central estimate is USD 17.0 bn, growing at about 9% to USD 31.1 bn by 2032. India still imports the majority of its devices by value, particularly high-end imaging, implants and IVD instruments, while it exports consumables, disposables and some equipment.

Policy is the story: the Production Linked Incentive scheme for devices, four medical device parks, the National Medical Devices Policy 2023, and the extension of CDSCO licensing to all device classes under the Medical Device Rules are reshaping supply. For hospital buyers the practical effect is more domestic options in consumables, orthopaedics, dialysis and patient monitoring, at 30–60% below imported prices.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 15.2 bn–USD 22.5 bn; differences are mostly scope.

Included: equipment, implants, consumables and disposables, IVD instruments and reagents, patient aids. Excluded: pharmaceuticals, hospital IT. Regulation: CDSCO under the Medical Device Rules 2017 (as amended); BIS standards; the proposed Drugs, Medical Devices and Cosmetics Bill.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• 70-80% of India's medical device demand is met through imports; imports ~USD 8.6 bn in FY2025 (Rubix Data Sciences)
• Exports FY2025 USD 4.01 bn (Rs 33,908.56 cr) to 187 countries; FY26 Apr-Dec USD 3.18 bn (IBEF)
• PLI for Medical Devices: outlay Rs 3,420 crore, 5% incentive on incremental sales, FY2022-23 to FY2026-27; 4 target segments (cancer care/radiotherapy; radiology & imaging; anaesthetics/cardio-respiratory/renal; implants) (India Briefing)
• Medical device parks scheme: Rs 400 crore, up to Rs 100 crore per park (70% of common infra; 90% in NE/hilly states); parks in Himachal Pradesh, Uttar Pradesh, Madhya Pradesh, Tamil Nadu (BioSpectrum Asia)
• Medical Devices Rules 2017 (under Drugs & Cosmetics Act 1940) classify devices A-D by risk with CDSCO oversight; 2020 amendments added UDI and post-market surveillance; CDSCO brought all device classes under MDR 2017 by Oct 2024 (BioSpectrum Asia / MRFR)
• ~800 manufacturers; key states Uttar Pradesh, Maharashtra, Haryana, Karnataka (Rubix Data Sciences)
• Top-5 suppliers hold 34-39% of revenue; Siemens Healthineers India ~8-11%, Wipro GE ~7-10%, Philips ~6-9% (Market Research Future)
• Top export destinations: US, France, Germany, Singapore, China, Turkey, Brazil, Netherlands, Iran, Belgium (IBEF)
• AP MedTech Zone (Visakhapatnam) hosts 100+ companies; Yamuna Expressway medical device park (Greater Noida, 350 acres) had 89 companies interested as of Jul 2025 (BioSpectrum Asia)

India

Demand concentrates in private hospital chains and diagnostics; public procurement runs through state corporations and GeM. Domestic manufacturing clusters (Gujarat, Maharashtra, Tamil Nadu, Telangana, Uttar Pradesh device park) are scaling in consumables, orthopaedics, cardiology (stents), dialysis and imaging (lower-end CT/X-ray).

GCC link

GCC buyers increasingly accept Indian-made consumables, implants and dialysis products with CE/ISO 13485 and SFDA/MOHAP registration; the price gap versus European and US products is 30–60%, which matters in framework tenders. The Consulting Wallah Network connects verified Indian manufacturers with GCC demand.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Manufacturers: CDSCO licence, ISO 13485 and CE are the baseline; exports to the GCC need SFDA/MOHAP registration through a local representative — plan 6–12 months.
• Hospital buyers (India): domestic alternatives now exist for most consumable and implant lines; tender with quality criteria rather than brand names.
• Investors: contract manufacturing and component supply inside device parks; distribution platforms serving tier-2/3 hospitals.

1. IBEF, Medical Devices Infographic May 2026 — ibef.org
2. BioVoice News / Rubix Data Sciences, India's medical devices industry likely to triple to $50 billion by 2030: Rubix Industry Insights — biovoicenews.com
3. India Briefing, India's Medical Devices Sector: PLI Progress & 2026 Outlook — india-briefing.com
4. IMARC Group, India Medical Devices Market Size, Share, Trends and Forecast 2026-2034 — imarcgroup.com
5. Towards Healthcare, India Medical Devices Market Size, Trends, Shares and Companies — towardshealthcare.com
6. Market Research Future, India Medical Devices Market — marketresearchfuture.com
7. BioSpectrum Asia (Frost & Sullivan), Policy Reforms Give India's MedTech Sector a Global Edge — biospectrumasia.com
8. Rubix Data Sciences (Rubix Industry Insights, via BioVoice News) (2026-02) — USD 15.2 bn (FY2025) (2025) to USD 50.1 bn (FY2030) (2030), CAGR 26.9%; scope: Industry size incl. domestic production + imports; India 4th largest in Asia, top-20 globally — source
9. IMARC Group (2026-09) — USD 19.11 bn (2025) to USD 31.85 bn (2034), CAGR 5.83% (2026-2034); scope: 2026E USD 20.23 bn — source
10. Towards Healthcare (2026-05) — USD 22.51 bn (2025) to USD 52.85 bn (2035), CAGR 8.91%; scope: Revenue basis — source
11. Market Research Future (2026) — USD 18.00 bn (2025) to USD 39.95 bn (2035), CAGR 8.3% (2026-2035); scope: 2026E USD 19.49 bn; top-5 suppliers hold 34-39% of revenue — source
12. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
13. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.